Free Trial

Regeneron Pharmaceuticals (REGN) News Today

→ Millionaire-Making “Wealth Pattern” Just Repeated on April 22 (From Paradigm Press) (Ad)
Free REGN Stock Alerts
$1,002.95
+2.16 (+0.22%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 7 at 4:34 PM | marketbeat.com
Bonnie L. Bassler Sells 827 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Bonnie L. Bassler sold 827 shares of the business's stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total value of $836,097.00. Following the sale, the director now owns 1,382 shares in the company, valued at approximately $1,397,202. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
June 7 at 10:10 AM | fool.com
Stock Split Watch: 3 Growth Stocks That Could Be Next
June 7 at 8:40 AM | marketbeat.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Public Employees Retirement Association of Colorado
Public Employees Retirement Association of Colorado raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,074 shares of t
June 6 at 12:19 PM | marketbeat.com
Top Biotech Stocks: Exploring Innovation Opportunities (REGN)
One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccines
June 6 at 10:34 AM | marketbeat.com
Capital World Investors Buys 23,146 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Capital World Investors grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,130,485 shares of the biopharmaceut
June 6 at 2:34 AM | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $1,200.00
June 5 at 11:25 PM | marketbeat.com
Cibc World Markets Corp Purchases 21,325 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Cibc World Markets Corp lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 117.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,496 shares of the biopharmace
June 5 at 3:25 PM | globenewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
June 5 at 12:43 PM | seekingalpha.com
Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript)
June 4 at 5:39 PM | marketbeat.com
Rhenman & Partners Asset Management AB Has $34.25 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Rhenman & Partners Asset Management AB reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,000 shares of
June 3, 2024 | insidermonkey.com
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?
June 3, 2024 | marketbeat.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Rafferty Asset Management LLC
Rafferty Asset Management LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,176 shares of the biopharmace
June 3, 2024 | marketbeat.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month High at $1,000.72
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 1-Year High at $1,000.72
June 3, 2024 | marketbeat.com
801 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Robinson Smith Wealth Advisors LLC
Robinson Smith Wealth Advisors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 801 shares of the biopharmaceutical company's stock, valued at appr
June 2, 2024 | americanbankingnews.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of "Moderate Buy" by Brokerages
June 1, 2024 | marketbeat.com
BOCHK Asset Management Ltd Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
BOCHK Asset Management Ltd bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,800 shares of the biopharmaceu
May 31, 2024 | globenewswire.com
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
May 31, 2024 | globenewswire.com
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 | globenewswire.com
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
May 31, 2024 | globenewswire.com
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 30, 2024 | prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
May 30, 2024 | marketbeat.com
TD Asset Management Inc Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
TD Asset Management Inc lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 43.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,513 shares of the biopha
May 30, 2024 | insidertrades.com
Michael S. Brown Sells 1,172 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock
May 29, 2024 | marketbeat.com
TFO Wealth Partners LLC Has $1.03 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
TFO Wealth Partners LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 58,400.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,170 shares of the biop
May 29, 2024 | marketbeat.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Sells $1,142,535.92 in Stock
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Michael S. Brown sold 1,172 shares of the firm's stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the transaction, the director now owns 1,382 shares of the company's stock, valued at approximately $1,347,256.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
May 29, 2024 | prnewswire.com
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
May 25, 2024 | marketbeat.com
Intech Investment Management LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Intech Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 119.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,593 shares of the bioph
May 25, 2024 | fool.com
2 Biotech Stocks to Buy in May
May 23, 2024 | globenewswire.com
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
May 23, 2024 | businesswire.com
Mary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering Fair
May 23, 2024 | marketbeat.com
Ontario Teachers Pension Plan Board Sells 995 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Ontario Teachers Pension Plan Board cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,971 shares of
May 23, 2024 | marketbeat.com
Regeneron Pharmaceuticals Q1 Earnings Transcript
May 23, 2024 | fool.com
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
May 22, 2024 | prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
May 22, 2024 | finance.yahoo.com
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?
May 21, 2024 | marketbeat.com
Dakota Wealth Management Purchases New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Dakota Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,372 shares of the biopharmaceutical compan
May 20, 2024 | marketbeat.com
Assetmark Inc. Acquires 1,552 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Assetmark Inc. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,171 shares of the biopharmaceutical company's stock
May 20, 2024 | globenewswire.com
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
May 20, 2024 | globenewswire.com
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
May 20, 2024 | investorplace.com
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 19, 2024 | marketbeat.com
1,061,803 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Norges Bank
Norges Bank bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,061,803 shares of the biopharmaceutical company's stock,
May 19, 2024 | marketbeat.com
ING Groep NV Has $24.87 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ING Groep NV reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 20.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,311 shares of the biopharmaceutical company's stock af
May 18, 2024 | insidertrades.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Leonard S. Schleifer Sells 22,830 Shares
May 18, 2024 | msn.com
Regeneron wins temporary restraining order preventing Eylea generic launch (update)
May 17, 2024 | marketbeat.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Nikko Asset Management Americas Inc.
Nikko Asset Management Americas Inc. decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,019 shares of the biopharmace
May 17, 2024 | marketbeat.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Sells $22,355,820.90 in Stock
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) CEO Leonard S. Schleifer sold 22,830 shares of the company's stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares in the company, valued at approximately $457,179,964.71. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
May 17, 2024 | globenewswire.com
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
May 17, 2024 | insidertrades.com
Leonard S. Schleifer Sells 25,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock
May 16, 2024 | marketbeat.com
Beacon Pointe Advisors LLC Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Beacon Pointe Advisors LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,786 shares of the biop
May 16, 2024 | businesswire.com
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
Get Regeneron Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Secret energy grid to power millions of homes (Ad)

This high-security, secret U.S. facility has 2,100 engineers, machinists, and technicians building a new type of energy system the world has never seen before.

Click here to get all the details.

REGN Media Mentions By Week

REGN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

REGN
News Sentiment
▼
0.53

0.73
▲
Average
Medical
News Sentiment

REGN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

REGN Articles
This Week
▼
17

15
▲
REGN Articles
Average Week

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:REGN) was last updated on 6/7/2024 by MarketBeat.com Staff

From Our Partners
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...
Colonial Metals | Sponsored
Shocking $16T Elon Musk Crypto Leak
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...
Crypto 101 Media | Sponsored
Millionaire-Making “Wealth Pattern” Just Repeated on April 22
If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.
Paradigm Press | Sponsored
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...
Crypto Swap Profits | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored